Whitegate Investment Counselors’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-744
Closed -$211K 74
2021
Q3
$211K Buy
744
+94
+14% +$30.8K 0.03% 217
2021
Q2
$225K Buy
+650
New +$197K 0.03% 212
2020
Q2
Sell
-650
Closed -$206K 195
2020
Q1
$206K Buy
+650
New +$197K 0.05% 168
2019
Q1
Sell
-883
Closed -$266K 200
2018
Q4
$266K Sell
883
-5
-0.6% -$1.6K 0.06% 161
2018
Q3
$314K Sell
888
-60
-6% -$20.7K 0.06% 158
2018
Q2
$275K Buy
948
+16
+2% +$4.5K 0.06% 161
2018
Q1
$255K Sell
932
-95
-9% -$29.5K 0.05% 166
2017
Q4
$327K Buy
1,027
+10
+1% +$3.21K 0.07% 150
2017
Q3
$318K Buy
1,017
+25
+3% +$7.4K 0.07% 150
2017
Q2
$269K Buy
992
+30
+3% +$7.93K 0.06% 157
2017
Q1
$263K Sell
962
-55
-5% -$15.6K 0.06% 157
2016
Q4
$288K Hold
1,017
0.08% 136
2016
Q3
$318K Buy
+1,017
New +$301K 0.09% 132

Other funds holding BIIB

Whitegate Investment Counselors's BIIB Position: Q4 2021 in Review

Whitegate Investment Counselors sold out of Biogen (BIIB) in Q4 2021, closing a stake of 744 shares — an estimated $211K sold.

Whitegate Investment Counselors first reported a position in BIIB in Q3 2016 and held it in 13 quarters. The position peaked at $327K in Q4 2017. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

  • Whitegate Investment Counselors reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
  • Whitegate Investment Counselors sold 744 Biogen shares in Q4 2021, an estimated $211K.
  • Whitegate Investment Counselors first reported a position in Biogen in Q3 2016 and held it in 13 quarters.
  • Whitegate Investment Counselors's Biogen position peaked at $327K in Q4 2017.
  • 1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Whitegate Investment Counselors's 13F filing for Q4 2021, filed 3 Feb 2022.